Jun 15, 2020   SOURCE: PR NewsWire

MenQuadfi (Quadrivalent Polysaccharide Tetanus Toxoid Conjugate Vaccine) Drug Overview

DUBLIN, June 15, 2020 /PRNewswire/ -- The "MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) Drug Overview" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Sanofi's MenQuadfi (quadrivalent polysaccharide tetanus toxoid conjugate vaccine) is a second-generation active polyvalent conjugate vaccine against group A, C, Y, and W meningococcal infection. It is presented as a sterile solution for injection containing Neisseria meningitidis capsular polysaccharide antigens individually conjugated to tetanus toxoid protein. Sanofi has submitted a Biologics License Application (BLA) for MenQuadfi to the US Food and Drug Administration (FDA) with a target action date of April 2020.

The report analysts expect a subsequent launch for persons aged 2 years in Q3 2020. The vaccine is currently in Phase III development in the EU. Following the initiation of the first of Sanofi's Phase III studies in July 2016, the report forecasts the vaccine's EU approval in individuals aged 12 months in Q3 2020, based on the expected submission timeline, with a launch date between Q4 2020 and Q1 2021. Sanofi also expects to file for an indication expansion in the US and EU in the upcoming years to include infants as young as six weeks old.

Key Topics Covered:

OVERVIEW

    --  Drug Overview
    --  Product Profiles
    --  MenQuadfi : Meningococcal vaccines

LIST OF TABLES

Table 1: MenQuadfi drug profile
Table 2: Late-phase trials of MenQuadfi for meningococcal vaccination
Table 3: MenQuadfi for meningococcal vaccination - SWOT analysis

For more information about this report visit https://www.researchandmarkets.com/r/waj94w

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/menquadfi-quadrivalent-polysaccharide-tetanus-toxoid-conjugate-vaccine-drug-overview-301076759.html

SOURCE Research and Markets